Company news

Clene Inc. news in 2026

Clene Inc.'s news releases, calls and decks from 2026, newest first.

View company

Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights

November 4, 2026

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

October 19, 2026

Clene to Present at Upcoming Investor Conferences

September 22, 2026

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA

September 21, 2026

Clene Announces $4 Million Registered Direct Offering

September 15, 2026

Clene to Present at Upcoming September Investor Conferences

September 3, 2026

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

August 14, 2026

Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval

August 10, 2026

Clene to Present at The Canaccord 46th Annual Growth Conference

July 29, 2026

Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

May 14, 2026

Clene Announces $7 Million Underwritten Offering of Common Stock

May 5, 2026

After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS

May 4, 2026

Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

March 11, 2026

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

February 23, 2026

Clene to Present at the Emerging Growth Conference

January 16, 2026

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

January 12, 2026

Clene Announces Registered Direct Offering of Over $28 Million

January 9, 2026

Decks in 2026